Personalized allele-specific antisense oligonucleotides for GNAO1-neurodevelopmental disorder.

Saved in:
Bibliographic Details
Title: Personalized allele-specific antisense oligonucleotides for GNAO1-neurodevelopmental disorder.
Authors: Shomer I; Cancer Research Center and Wohl Institute for Translational Medicine, Tel Hashomer, Ramat Gan, Israel., Mor N; Cancer Research Center and Wohl Institute for Translational Medicine, Tel Hashomer, Ramat Gan, Israel., Raviv S; Cancer Research Center and Wohl Institute for Translational Medicine, Tel Hashomer, Ramat Gan, Israel., Budick-Harmelin N; Cancer Research Center and Wohl Institute for Translational Medicine, Tel Hashomer, Ramat Gan, Israel., Matchevich T; Cancer Research Center and Wohl Institute for Translational Medicine, Tel Hashomer, Ramat Gan, Israel., Avkin-Nachum S; Cancer Research Center and Wohl Institute for Translational Medicine, Tel Hashomer, Ramat Gan, Israel., Rais Y; Cancer Research Center and Wohl Institute for Translational Medicine, Tel Hashomer, Ramat Gan, Israel., Haffner-Krausz R; Department of Veterinary Resources, Weizmann Institute of Science, Rehovot, Israel., Haimovich A; Cancer Research Center and Wohl Institute for Translational Medicine, Tel Hashomer, Ramat Gan, Israel., Ziv A; Cancer Research Center and Wohl Institute for Translational Medicine, Tel Hashomer, Ramat Gan, Israel., Fluss R; Cancer Research Center and Wohl Institute for Translational Medicine, Tel Hashomer, Ramat Gan, Israel., Ben-Ze'ev B; Sheba Medical Center, Edmond and Lilly Safra Children's Hospital, Tel Hashomer, Israel., Heimer G; Sheba Medical Center, Edmond and Lilly Safra Children's Hospital, Tel Hashomer, Israel., Silachev DN; Institute of Life Sciences and Biomedicine, Far Eastern Federal University, 690090 Vladivostok, Russia.; A.N. Belozersky Research Institute of Physico-Chemical Biology, Moscow State University, 119992 Moscow, Russia.; Department of Cell Physiology and Metabolism, Faculty of Medicine, Translational Research Center in Oncohaematology, University of Geneva, 1211 Geneva, Switzerland., Katanaev VL; Institute of Life Sciences and Biomedicine, Far Eastern Federal University, 690090 Vladivostok, Russia.; Department of Cell Physiology and Metabolism, Faculty of Medicine, Translational Research Center in Oncohaematology, University of Geneva, 1211 Geneva, Switzerland., Dominissini D; Cancer Research Center and Wohl Institute for Translational Medicine, Tel Hashomer, Ramat Gan, Israel.; Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Source: Molecular therapy. Nucleic acids [Mol Ther Nucleic Acids] 2024 Dec 22; Vol. 36 (1), pp. 102432. Date of Electronic Publication: 2024 Dec 22 (Print Publication: 2025).
Publication Type: Journal Article
Journal Info: Publisher: Cell Press Country of Publication: United States NLM ID: 101581621 Publication Model: eCollection Cited Medium: Print ISSN: 2162-2531 (Print) Linking ISSN: 21622531 NLM ISO Abbreviation: Mol Ther Nucleic Acids Subsets: PubMed not MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2162-2531
DOI:10.1016/j.omtn.2024.102432